Radiation, Cetuximab and Pemetrexed With or Without Bevacizumab in Locally Advanced Head and Neck Cancer
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the effects (good and bad) of chemoradiotherapy with
or without Bevacizumab (Avastin). Chemoradiotherapy is the combination of chemotherapy (the
drugs pemetrexed and cetuximab) and radiation. Pemetrexed is not approved by the Food and
Drug Administration (FDA) for head and neck cancer when used in combination with radiation
therapy. Cetuximab is also approved by the FDA for head and neck cancers in patients who have
failed other chemotherapy treatments. Bevacizumab is approved by the Food and Drug
Administration (FDA) for colorectal cancer and non-small cell lung cancer in combination of
chemotherapy. In this study, the use of bevacizumab is investigational.